Of note, de novo ATP6AP2 deletion variants have also been described in neurological disease, altering neuronal development, LC3b abundance and lysosomal function when modelled in the mouse and human stem cell-derived neurons [56, 57]. This evidence concerns the gene MAP1LC3B and nervous system disorder.